Celerion: expansion of ADME services
Contract development and manufacturing organization Celerion has announced plans to invest in expanding its absorption, distribution, metabolism, and excretion (ADME) suite of services. The expansion investment will include increasing laboratory space, additional capabilities, and dedicated customer service team.
“With over 100 radiolabeled studies and 800 participants dosed, our experience in ADME studies ensures clients’ studies run efficiently and effectively from initial planning through to the final report,” said Phil Bach, Celerion’s vice president of global clinical research. “Additionally, our clinical and bioanalytical services are located within the same facility, enabling faster access to quality data and savings in time and cost.”
